MI-HARMAN
14.9.2022 15:27:35 CEST | Business Wire | Press release
HARMAN International, a wholly-owned subsidiary of Samsung Electronics Co., Ltd. focused on connected technologies and solutions for automotive, consumer and enterprise markets, today announced the introduction of Ready Care — the latest solution in its expanding portfolio of products designed and built to deliver consumer-focused experiences at an automotive grade. Ready Care is a set of solutions — Cognitive Distraction, Stress-Free Routing, and Personalized Comfort — that can work together or independently to improve safety and reduce driver stress.
Ready Care delivers heightened levels of safety and wellbeing through the integration of several key technologies. In addition to employing cameras that can detect driver drowsiness, Ready Care measures real-time driver cognitive load to identify when potential distractions arise, and then offers tailored intervention strategies to maximize safety. The experience is powered by newly developed machine learning algorithms, which gather and process data from in-vehicle cameras and sensors to monitor a driver’s state. Ready Care can then generate customized in-vehicle cabin prompts to trigger a range of behavioral responses — increasing awareness, alleviating stress, or stimulating relief.
“Safety remains a top concern for consumers when considering a new vehicle purchase, and now, with Ready Care, OEMs can improve vehicle safety in a significant new way,” said Armin Prommersberger, Senior Vice President, Automotive Product Management at HARMAN International. “Ready Care is essentially a co-pilot, spotting when distractions could turn into dangerous situations and intervening to avoid them. For the first time, the vehicle can, in a sense, know what the driver is thinking; this is a game changer. We are incredibly proud of and excited by the impact Ready Care will have for drivers, passengers, and everyone on the road.”
Key features of Ready Care include:
- Eyes and Mind on Road: Ready Care measures both driver eye activity and state of mind. An infra-red global shutter camera with active illumination surveys the driver’s face in low and high light environments to provide real-time data into facial expressions, eye gaze, eyelid openings, and more. The HARMAN Cognitive Distraction feature — a real-time driver visual and cognitive load measurement tool — deciphers when the driver is mentally distracted and can initiate multiple and simultaneous in-cabin vehicle intervention responses. It measures real-time driver cognitive load and separates driving tasks from other mental activities as well as visual and manual distractions to enable tailored intervention strategies that maximize safety.
- Stress-free Routing: Compatible with multiple navigation engines, Ready Care provides an alternate route selection to lower elevated driver stress levels while on the road. Through detecting real-time stress factors like traffic jams or weather and adapting accordingly, this solution helps mitigate the driver’s state of stress or anxiety.
- Personalized Experiences: As all journeys and drivers are unique, Ready Care leverages advanced machine learning technology to provide personalized intervention strategies tailored to the individual and their driving experience. Ready Care delivers closed-loop interventions via an SDK, allowing OEMs and third parties to integrate any vehicle feature or function — such as HVAC control, media content and volume, or seat sensors — into the Ready Care solution. An example could be the advanced technologies offered by Gentherm, the global market leader of innovative thermal management and pneumatic comfort technologies for the automotive industry.
Ready Care equips OEMs with advanced but meaningful technology to improve driver safety and wellbeing. Automotive manufacturers have the opportunity to incorporate the full set of Ready Care solutions into vehicles or choose specific features to create a more customized solution right for their customers and fleets.
For decades, HARMAN has been uniquely positioned at the intersection of automotive and consumer technology innovation, resulting in meaningful, industry-leading solutions. Through its key consumer and technology brands, deep industry expertise, and robust technology stack, HARMAN is equipped to deliver on the promise of consumer experiences through automotive-grade solutions today.
For more information on HARMAN’s Ready Care solution, visit car.harman.com/experiences/ready-care.
About HARMAN
HARMAN (harman.com) designs and engineers connected products and solutions for automakers, consumers, and enterprises worldwide, including connected car systems, audio and visual products, enterprise automation solutions; and services supporting the Internet of Things. With leading brands including AKG®, Harman Kardon®, Infinity®, JBL®, Lexicon®, Mark Levinson® and Revel®, HARMAN is admired by audiophiles, musicians and the entertainment venues where they perform around the world. More than 50 million automobiles on the road today are equipped with HARMAN audio and connected car systems. Our software services power billions of mobile devices and systems that are connected, integrated and secure across all platforms, from work and home to car and mobile. HARMAN has a workforce of approximately 30,000 people across the Americas, Europe, and Asia. In 2017, HARMAN became a wholly-owned subsidiary of Samsung Electronics Co., Ltd.
© 2022 HARMAN International Industries, Incorporated. All rights reserved. Harman Kardon, Infinity, JBL, Lexicon and Mark Levinson are trademarks of HARMAN International Industries, Incorporated, registered in the United States and/or other countries. AKG is a trademark of AKG Acoustics GmbH, registered in the United States and/or other countries. Features, specifications, and appearance are subject to change without notice.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220914005609/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
